Japanese man with HCV genotype 4 infection and cirrhosis who was successfully treated by the combination of glecaprevir and pibrentasvir

Mai Totsuka; Masayuki Honda; Tatsuo Kanda; Tomotaka Ishii; Naoki Matsumoto; Yoichiro Yamana; Tomohiro Kaneko; Taku Mizutani; Hiroshi Takahashi; Mariko Kumagawa; Reina Sasaki; Ryota Masuzaki; Shini Kanezawa; Kazushige Nirei; Hiroaki Yamagami; Shunichi Matsuoka; Hiroshi Ohnishi; Hiroaki Okamoto; Mitsuhiko Moriyama

doi:10.2169/internalmedicine.6728-20

Japanese man with HCV genotype 4 infection and cirrhosis who was successfully treated by the combination of glecaprevir and pibrentasvir

Mai Totsuka, Masayuki Honda, Tatsuo Kanda, Tomotaka Ishii, Naoki Matsumoto, Yoichiro Yamana, Tomohiro Kaneko, Taku Mizutani, Hiroshi Takahashi, Mariko Kumagawa, Reina Sasaki, Ryota Masuzaki, Shini Kanezawa, Kazushige Nirei, Hiroaki Yamagami, Shunichi Matsuoka, Hiroshi Ohnishi, Hiroaki Okamoto, Mitsuhiko Moriyama

School of Medicine

Research output: Contribution to journal › Review article › peer-review

1 Citation (Scopus)

Abstract

A 74-year-old man with a history of transfusion at 35 years old in Egypt was referred to our hospital. He was infected with hepatitis C virus (HCV) genotype 4 (GT4), which is a rare HCV GT in Japan, and was also diagnosed with hepatic compensated cirrhosis. We safely treated the patient for 12 weeks with the combination of glecaprevir and pibrentasvir, and a sustained virologic response (SVR) was achieved. This is the first report of HCV GT4 infection in a treatment-naïve Japanese patient with cirrhosis in whom SVR was achieved with the combination treatment of glecaprevir and pibrentasvir.

Original language	English
Pages (from-to)	2061-2066
Number of pages	6
Journal	Internal Medicine
Volume	60
Issue number	13
DOIs	https://doi.org/10.2169/internalmedicine.6728-20
Publication status	Published - 2021

Keywords

Cirrhosis
DAA
HCV genotype 4
Japan
Transfusion

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2169/internalmedicine.6728-20

Cite this

Totsuka, M., Honda, M., Kanda, T., Ishii, T., Matsumoto, N., Yamana, Y., Kaneko, T., Mizutani, T., Takahashi, H., Kumagawa, M., Sasaki, R., Masuzaki, R., Kanezawa, S., Nirei, K., Yamagami, H., Matsuoka, S., Ohnishi, H., Okamoto, H., & Moriyama, M. (2021). Japanese man with HCV genotype 4 infection and cirrhosis who was successfully treated by the combination of glecaprevir and pibrentasvir. Internal Medicine, 60(13), 2061-2066. https://doi.org/10.2169/internalmedicine.6728-20

@article{2e03b16690ce4ab996015682d3a57862,

title = "Japanese man with HCV genotype 4 infection and cirrhosis who was successfully treated by the combination of glecaprevir and pibrentasvir",

abstract = "A 74-year-old man with a history of transfusion at 35 years old in Egypt was referred to our hospital. He was infected with hepatitis C virus (HCV) genotype 4 (GT4), which is a rare HCV GT in Japan, and was also diagnosed with hepatic compensated cirrhosis. We safely treated the patient for 12 weeks with the combination of glecaprevir and pibrentasvir, and a sustained virologic response (SVR) was achieved. This is the first report of HCV GT4 infection in a treatment-na{\"i}ve Japanese patient with cirrhosis in whom SVR was achieved with the combination treatment of glecaprevir and pibrentasvir.",

keywords = "Cirrhosis, DAA, HCV genotype 4, Japan, Transfusion",

author = "Mai Totsuka and Masayuki Honda and Tatsuo Kanda and Tomotaka Ishii and Naoki Matsumoto and Yoichiro Yamana and Tomohiro Kaneko and Taku Mizutani and Hiroshi Takahashi and Mariko Kumagawa and Reina Sasaki and Ryota Masuzaki and Shini Kanezawa and Kazushige Nirei and Hiroaki Yamagami and Shunichi Matsuoka and Hiroshi Ohnishi and Hiroaki Okamoto and Mitsuhiko Moriyama",

year = "2021",

doi = "10.2169/internalmedicine.6728-20",

language = "English",

volume = "60",

pages = "2061--2066",

journal = "Internal Medicine",

issn = "0918-2918",

publisher = "Japanese Society of Internal Medicine",

number = "13",

}

Totsuka, M, Honda, M, Kanda, T, Ishii, T, Matsumoto, N, Yamana, Y, Kaneko, T, Mizutani, T, Takahashi, H, Kumagawa, M, Sasaki, R, Masuzaki, R, Kanezawa, S, Nirei, K, Yamagami, H, Matsuoka, S, Ohnishi, H, Okamoto, H & Moriyama, M 2021, 'Japanese man with HCV genotype 4 infection and cirrhosis who was successfully treated by the combination of glecaprevir and pibrentasvir', Internal Medicine, vol. 60, no. 13, pp. 2061-2066. https://doi.org/10.2169/internalmedicine.6728-20

TY - JOUR

T1 - Japanese man with HCV genotype 4 infection and cirrhosis who was successfully treated by the combination of glecaprevir and pibrentasvir

AU - Totsuka, Mai

AU - Honda, Masayuki

AU - Kanda, Tatsuo

AU - Ishii, Tomotaka

AU - Matsumoto, Naoki

AU - Yamana, Yoichiro

AU - Kaneko, Tomohiro

AU - Mizutani, Taku

AU - Takahashi, Hiroshi

AU - Kumagawa, Mariko

AU - Sasaki, Reina

AU - Masuzaki, Ryota

AU - Kanezawa, Shini

AU - Nirei, Kazushige

AU - Yamagami, Hiroaki

AU - Matsuoka, Shunichi

AU - Ohnishi, Hiroshi

AU - Okamoto, Hiroaki

AU - Moriyama, Mitsuhiko

PY - 2021

Y1 - 2021

N2 - A 74-year-old man with a history of transfusion at 35 years old in Egypt was referred to our hospital. He was infected with hepatitis C virus (HCV) genotype 4 (GT4), which is a rare HCV GT in Japan, and was also diagnosed with hepatic compensated cirrhosis. We safely treated the patient for 12 weeks with the combination of glecaprevir and pibrentasvir, and a sustained virologic response (SVR) was achieved. This is the first report of HCV GT4 infection in a treatment-naïve Japanese patient with cirrhosis in whom SVR was achieved with the combination treatment of glecaprevir and pibrentasvir.

AB - A 74-year-old man with a history of transfusion at 35 years old in Egypt was referred to our hospital. He was infected with hepatitis C virus (HCV) genotype 4 (GT4), which is a rare HCV GT in Japan, and was also diagnosed with hepatic compensated cirrhosis. We safely treated the patient for 12 weeks with the combination of glecaprevir and pibrentasvir, and a sustained virologic response (SVR) was achieved. This is the first report of HCV GT4 infection in a treatment-naïve Japanese patient with cirrhosis in whom SVR was achieved with the combination treatment of glecaprevir and pibrentasvir.

KW - Cirrhosis

KW - DAA

KW - HCV genotype 4

KW - Japan

KW - Transfusion

UR - http://www.scopus.com/inward/record.url?scp=85109978967&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.6728-20

DO - 10.2169/internalmedicine.6728-20

M3 - Review article

C2 - 33518580

AN - SCOPUS:85109978967

SN - 0918-2918

VL - 60

SP - 2061

EP - 2066

JO - Internal Medicine

JF - Internal Medicine

IS - 13

ER -

Japanese man with HCV genotype 4 infection and cirrhosis who was successfully treated by the combination of glecaprevir and pibrentasvir

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this